This study is a Phase 1/2 randomized, double-blind, placebo-controlled, single- and multiple-dose study with staggered dose escalations in healthy volunteers.
Following completion of SAD and MAD cohorts, healthy volunteers will participate in administration of VT7208 with and without food to determine the effect of a fasted or fed state on pharmacokinetics.
Participants with MS will be recruited for part 3 of this study.
This study consists of 3 parts, as follows:
Part 1: SAD in healthy volunteers with a single dose administration of VT7208 or placebo and collection of study data.
MAD in healthy volunteers with multiple dose administration of VT7208 or placebo and collection of study data.
Part 2:
Food effect cohort in healthy volunteers. Participants will be randomized to receive open label VT7208 in either a fasted state or a fed state, and will receive the opposite at the next admission to the study site.
Part 3:
Participants MS will receive VT7208 with dose determined from Parts 1 and 2. Participation in this section will entail weekly study visits for administration of study medication and collection of study data.
